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Abstract 
 
This study aims to demonstrate the type of pharmacodynamic interaction and the demonstration of an 
antinociceptive action of fixed-ratio binary combinations between a non-opioid analgesic 
(acetaminophen) and an anticonvulsant (carbamazepine) as a rational way to treat pain. All experimental 
procedures used in this study were closely in line with international bioethical regulations on 
experiments conducted on laboratory animals. For quantifying the interaction, we used the method of the 
additive composite curve, which allows the quantitative assessment of the pharmacodynamic 
interactions of binary combinations in fixed proportion. The interaction between these substances is the 
synergistic (potentiation), as evidenced by the left shift of the regression curve of the combination 
compared to the composite additive curve. The statistical parameters of regression analysis reveal the 
synergism between the two substances (Zmix = 39.276 ± 7.54 mg / kg ( Zmix < Zadd ) the interaction 
index Ȗ = 0.387 , p < 0.05, tc = 3.753 , tt = 3.511 , Fc = 10.825 , Ft = 4.260 ). The synergism between the two 
substances is explained by the specific action mechanisms of each substance 
 
Rezumat 
 
Studiul de faĠă îúi propune investigarea tipului de interacĠiune farmacodinamicăúi demonstrarea acĠiunii 
antinociceptive a unei combinaĠii binare în proporĠie fixă între un analgezic non-opoid (Acetaminofen) úi 
un anticonvulsivant (carbamazepină) ca o modalitate raĠională de tratament al durerii. Toate procedeele 
experimentale utilizate în realizarea acestui studiu au fost în strânsă concordanĠă cu reglementările 
bioetice internaĠionale referitoare la experienĠele realizate pe animale de laborator.  Pentru cuantificarea 
interacĠiunii s-a utilizat metoda dreptei aditive compuse, care permite evaluarea cantitativă a 
interacĠiunilor de tip farmacodinamic din combinaĠiile binare în proporĠie fixă. InteracĠiunea între aceste 
substanĠe este de tip sinergic (potenĠare), dovedită prin deplasarea la stânga a dreptei de regresie a 
asocierii faĠă de dreapta aditivă compusă. Parametrii statistici ai analizei de regresie pun în evidenĠă 
sinergismul dintre cele două substanĠe (Zmix = 39.276 ± 7.54 mg/kg (Zmix < Zadd), indice de interacĠiune 
Ȗ = 0,387, p < 0.05, tc = 3.753, tt = 3.511, Fc = 10.825, Ft = 4.260). Sinergismul dintre cele două substanĠe 
se explică prin mecanismele de acĠiune specifice fiecărei substanĠe.  
 
Introduction 
 
Modern analgesic therapy is currently 
dominated by two major classes of analgesic 
drugs namely opioid  and  non-opioid 
analgesics (analgesic, antipyretic and anti-
inflammatory drugs NSAIDs).  
In what concerns the analgesic NSAID 
substances, a host of new improved 
synthetic variants have been developed, as 
well as a set of optimized routes of 
administration,  but  the  conceptual 
innovations  have  not  been  entirely 
satisfactory. This is probably due to the 
relatively slow advance in the understanding 
of the pathogenesis of inflammatory pain.  
On the other hand, a principle 
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combinations, as a reasonable way of 
improving the treatment of pain, is that 
associating drugs with different mechanisms 
of action, we can obtain a multimodal 
coverage of a broader spectrum of types of 
pain. Therefore we can create the possibility 
that the interaction to be greater than 
additive, i.e. synergistic (potentiation) [14]. 
In our studies were taken into 
consideration the role of pro-inflammatory 
cytokines in pathological pain states [22].  
In this paper, we attempt to consider the 
prospects of associations (combinations) 
between drugs that influence pain in 
inflammatory processes  
 
1. Materials and Methods 
 
The research we used Swiss male mice 
(Source Cantacuzino Institute, Bucharest) 
weighing 20-25 g. Habitation conditions were 
established  within  the  laboratory  of 
experimental pharmacodynamics of  the 
department  of  Pharmacodynamics  and 
Clinical Pharmacy, University “Grigore T. 
Popa” Iaúi, in a room with controlled 
temperature and humidity (21°C ±2°C), and 
a cycle of light/dark, 12 / 12 hours (07.00AM 
/ 07.00PM).  
The animals were housed in plexiglas 
cages (8-10 individuals per cage) provided 
with water-drippers. They received standard 
adfood and water (Băneasa Biobase).  
The tests were conducted from 10.00 
AM. 3 hours before the test, access to food 
and water was discontinued. 
All experimental procedures used in this 
study were in close agreement with the 
specific norms approved by the “Grigore T. 
Popa” University of Medicine following the 
bioethical  and  international  regulations 
relating to experiments conducted on 
laboratory animals [23].  
In this study, the following substances 
were used:  
x acetaminophen (paracetamol) (Sigma),  
x carbamazepine (Sigma),  
x  Zymosan A (Sigma),  
x  Carboxy-methyl-cellulose-Na (Sigma)  
x  saline (Zentiva).  
 
Carbamazepine  and  acetaminophen 
were administered alone and in combination 
orally, with doses in a geometric sequence.  
We used a model of nociception with 
chemical stimulus,  specific  for  the 
inflammatory pain, in this study the 
abdominal constriction response test (the 
method of Siegmund et al. 1957, the 
technique of Koster et al. 1959) [20].  
The  method  consists  of  the 
intraperitoneal  administration  of  a 
suspension of zymosan A at a dose of 
40mg/kg to the mouse. The number of 
abdominal  constriction  responses  is 
recorded, for a duration of 12 minutes after 
the administration of irritants [21].  
Data  interpretation  was  quantal, 
characterized by the presence or absence of 
responses,  calculating  the  maximum 
possible effect:  
 
% (antinociception) inhibition = (no. non-
responder / total No. of animals) x 100 [19]. 
 
For quantifying the interaction, we used 
the method of the additive composite curve, 
which allows the quantitative assessment of 
pharmacodynamic interactions of binary 
combinations in fixed proportion [17, 18].  
The method is based on the analysis of 
the regression curve, the regression curve of 
the addition compared to the additive 
composite line for a 50% level of activity.  
The interaction index indicates the 
strength of the synergism. The statistical 
analysis for all tests statistical significance 
was considered statistically significant for P 
values < 0.05 (ANOVA test, t - test). 
 
2. Results and Discussions 
 
We  administered  orally  successive 
doses of acetaminophen (paracetamol) in 
geometric progression. The dose range was 
of 50.00-600.00 mg kgbw
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Using such an administration pattern, it 
was possible to obtain a maximum effect of 
100% for a dose of 600 mgkgbw
-1.  
The data allowed determining the ED50 
of acetaminophen (paracetamol). (Table 1) 
We  administered  orally  successive 
doses of carbamazepine in geometric 
progression, between 7.5-60.00 mgkgbw
-1.  
We were able to obtain a maximum 
effect of 80% for the dose of 60 mg/ kgbw
-1.  
The data allowed the determination of 
ED50 value of carbamazepine. (Table 1). 
 
Table 1 
 
ED50 for the drugs administered alone 
 
Value  Acetaminophen  Carbamazepine 
(CBZ) 
ED50 
(SEM)
1 
mgkgbw
-
1p.o 
162.48 (26.24) 
Y = -2.367 +3.33*X 
R = 0.948 
41.14 (12.20) 
Y = 0.59 +2.72*X 
R = 0.976 
1SEM, Standard error of the mean 
 
The data in Table 1 allow for plotting the 
regression line for the composite additive 
curve, necessary for the determination of the 
Zadd value (Fig. 1). 
 
 
 
Fig. 1 Analysis of the composite additive line of 
the combination CBZ-Acetaminophen 
(paracetamol) 
 
From the analysis of the regression line 
(Fig 1) and table 1 we can observe that we 
have been able to demonstrate an 
antinociceptive  effect of carbamazepine 
(ED50 = 41.14 ±12.20 mgkgbw
-1) and of 
acetaminophen (paracetamol) (162.48  ± 
26.24 mg/kg) using the nociception model 
taken in study. After finding those values, we 
have calculated a value of Zadd = 101.59 ± 
14.54 mgkgbw
-1 and the ratios of the two 
substances. After administration of the 
combination in fixed proportion, successive 
series of doses in geometric progression, we 
found the following:  
Zmix = 39.276 ± 7.54 mg / kg (Zmix < Zadd),  
an  interaction index Ȗ = 0.387, p <0.05 
(Table 2). The interaction between these 
substances is of the synergistic (potentiation) 
type. This is proven by the left shift of the 
regression line compared to the composed 
additive line for the combination (Fig 2).  
The statistical parameters of the 
regression  analysis  reveal  synergism 
between the two substances (tc = 3.753, tt = 
3.511, Fc = 10.825, Ft = 4.260). 
 
 
 
Fig. 2 Regression line for the combination 
acetaminophen (paracetamol)-CBZ compared to 
the additive composite line 
Table 2 
ED50 for the combinations of the drugs taken in the study 
 
Substance  Total dose 
mgkgbw
-1, p.o. 
Maximal 
possible effect 
(MPE) % 
ED50 (SEM) 
Zadd (SEM)  Zmix (SEM) 
Acetaminophene / 
CBZ (0.798/0.202) 
12.20  16.66 
101.59 (14.54) 
Y = 3.02 + 0.57*X 
R = 0.959 
39.276 (7.54)
1 
Y = -3.17 + 4.97*X 
R = 0.953 
Interaction index=0.387 
25.40  33.33 
50.80  66.66 
101.59  100.00 
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The abdominal constriction response 
test allows the assessment of central and 
peripheral analgesia. The test can use a 
number of irritating agents such as 
acetylcholine bromide, acetic acid, Zymosan 
A. Using the irritating agent Zymosan A the 
model receives a specificity for the 
pathogenesis of inflammatory pain [12, 21]. 
Authors have shown that intraperitoneal 
administration of zymosan in mice induces 
an inflammatory response, characterized by 
the abdominal constriction response, plasma 
extravasations, leukocyte infiltration and 
biosynthesis of eicosanoids [Doherty cit. 
Pettipher [12]. 
Recently  it  was  revealed  that 
inflammatory agents do not directly stimulate 
the release of primary hyper nociceptive 
mediators, but that their release is preceded 
by a cascade of cytokines [5, 15]  
It was revealed that the mouse 
abdominal constriction response to zymosan 
and acetic acid is mediated by TNF-D, IL1-E 
and IL8, which act synergistically and 
simultaneously [15]. 
Acetaminophen  (paracetamol)  has 
analgesic and antipyretic effects similar to 
NSAIDs.  
However, in contrast, acetaminophen 
(paracetamol) taken in therapeutic doses 
has very low or non-existent antiplatelet or 
anti-inflammatory activity and does not show 
any side effect like of the NSAIDs, such as 
gastrointestinal injury or bronchoconstriction 
induced by acetyl salicylic acid.  
Therefore,  acetaminophen  widely 
replaced aspirin and other salicylates in the 
treatment of mild to moderate pain that is not 
associated with inflammatory processes, 
such as headaches, toothaches and 
dysmenorrheal [2].  
Although it has been synthesized many 
years ago and used extensively in the 
treatment of pain, its mechanism of action is 
still unknown. The most probable major 
mechanism however remains the inhibition 
of cyclooxygenase. Some studies have 
tested the possible interference between 
acetaminophen and NOS (nitric oxide 
synthase) both constitutive and inducible [2], 
while other studies support the hypothesis of 
an activating component of the opioid 
descending spinal pathways [13].  
Other studies present actions on the 
spinal TRPA1, which is considered one of 
the most important triggers on pain at the 
spinal level.  
Acetaminophen  metabolites  activate 
native TRPA1 and reduce voltage-gated 
calcium and sodium currents in primary 
sensory neurons, thus inducing an analgesic 
effect [1]. 
One of the analgesic mechanisms of 
acetaminophen is inhibiting the uptake of 
anandamide and other endocannabinoids 
from the extracellular space.  
The results imply that modulation of the 
endocannabinoid system in addition to other 
mechanisms  mediate  the  synergistic 
antinociceptive effects of acetaminophen 
combinations [10].  
Carbamazepine  is a  drug  with 
anticonvulsant action, useful in various types 
of epilepsy, but which is lately used in clinic 
in certain types of pain, like the trigeminal 
neuralgia [16]. 
The action of the drug is explained by 
their blocking of the Na
+ channels. We know 
several subtypes denoted by Nav 1.1 to 1.9. 
Nav1.7, 1.8 and 1.9 are expressed only in 
peripheral sensory  neurons and  are 
considered to be involved in both the 
initiation of the acute pain and in maintaining 
the post-lesion inflammatory hyperalgesia. 
Nav  1.4 channels, 1.6, 1.7 are sensitive to 
tetrodotoxin (TTX), while Nav 1.5, 1.8, 1.9, 
are TTX-resistant [7-9]. 
The  Nav1.7  subtype  is expressed 
significantly in the dorsal root ganglion 
neurons (DRG) in the myenteric and 
sympathetic neurons, while Nav1.8  is 
expressed preferentially in DRG and Gasser 
ganglia. Its implication in inflammatory pain Chiаac et al.                                                                                                                     Medicamentul Veterinar / Veterinary Drug 
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and cold-induced pain stimulus is well 
documented [4].  
It is known that the Nav1.7 subtype is 
sensitive to carbamazepine and its mutations 
cause a number of hereditary pain 
syndromes [11]. 
Nav1.9 is expressed in sensory neurons 
and in the enteric nervous system, especially 
in the small neurons with nociceptive 
properties. In light of this knowledge Nav1.7, 
1.8, and 1.9 could be important targets for 
analgesic drugs [7]. 
 
Conclusions 
 
The synergism obtained in research 
presented in this paper can be explained by 
the specific action mechanisms of the 
substances taken in study.  
Usually, synergistic effects are obtained 
when two drugs with at least one different 
action mechanism are combined.  
In the case of carbamazepine and 
acetaminophen (paracetamol), there are 
several mechanisms at play, which might 
concur for obtaining such a clear effect:  
 
x carbamazepine,  blocks  the  ionic 
channels involved in the generation 
and transport of nociceptive sensations 
at the level of the spinal nerve and the 
medulla,  
x acetaminophen, might inhibit the local 
generation of inflammatory mediators 
by the presumed COX inhibition; 
x inhibit the generation of sodium / 
calcium potentials in primary sensory 
nociceptive  neurons  by  activating 
TRPV ; 
x modulate the endocannabinoid spinal 
pathways, reducing pain transmission 
at the spinal level. 
 
Anyway, acetaminophen (paracetamol) 
seems to remain a potent analgesic and 
might enjoy a new period of glory as member 
in various drug combination with stronger 
analgesic properties.  
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